Sarepta Therapeutics Inc (SRPT) — Long-term Investment Intensity
Sarepta Therapeutics Inc (SRPT) has a Long-term Investment Intensity of 0.3% as of December 2025. Long-term investments of $10.57 Million represent 0.3% of total assets of $3.35 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See net assets of Sarepta Therapeutics Inc for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Sarepta Therapeutics Inc Long-term Investment Intensity (2017–2025)
This chart shows how Sarepta Therapeutics Inc's Long-term Investment Intensity has evolved across 9 annual periods from 2017 to 2025. As of December 2025, the intensity stands at 0.3%, reflecting long-term investments of $10.57 Million against total assets of $3.35 Billion USD. Also explore SRPT asset base for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for Sarepta Therapeutics Inc (2017–2025)
The table below presents the year-by-year Long-term Investment Intensity for Sarepta Therapeutics Inc from 2017 to 2025, covering 9 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see SRPT market cap.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 0.3% | $10.57 Million | $3.35 Billion | ▼ -3.1 pp |
| 2024 | 3.5% | $136.87 Million | $3.96 Billion | ▲ +3.3 pp |
| 2023 | 0.2% | $6.53 Million | $3.26 Billion | ▼ -0.8 pp |
| 2022 | 1.0% | $31.32 Million | $3.13 Billion | ▼ -0.1 pp |
| 2021 | 1.1% | $34.89 Million | $3.15 Billion | ▼ -0.2 pp |
| 2020 | 1.3% | $38.80 Million | $2.98 Billion | ▼ -0.5 pp |
| 2019 | 1.8% | $31.94 Million | $1.82 Billion | ▼ -4.8 pp |
| 2018 | 6.5% | $107.29 Million | $1.64 Billion | ▲ +4.9 pp |
| 2017 | 1.7% | $21.81 Million | $1.31 Billion | — |